FDA approves updated labeling for Talzenna plus Xtandi in men with HRR gene-mutated metastatic prostate cancer, showing a ...

FDA updates talazoparib and enzalutamide labeling, confirming survival benefits for HRR-mutated mCRPC, while excluding ...

This headline and story have been updated to clarify that the FDA approval was for an expanded indication to treat acute HCV.

AbbVie Inc. (NYSE:ABBV) is one of the 12 best healthcare stocks to buy now. On June 12, the US Food and Drug Administration (FDA) approved the company’s Mavyret treatment label expansion. The approval ...

The US Food and Drug Administration (FDA) has approved the label expansion of AbbVie’s Mavyret (glecaprevir/pibrentasvir).

The U.S. Food and Drug Administration (FDA) approved a label expansion for AbbVie Inc’s (NYSE:ABBV) Mavyret ...

Incyte (NASDAQ:INCY) announced Wednesday that the U.S. Food and Drug Administration (FDA) approved a label expansion for its ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Data from the Phase 3, multicenter, single-arm prospective study evaluating the safety and efficacy of Mavyret eight-week treatment in adults with acute HCV infection supported the label expansion.

AbbVie’s Mavyret receives US FDA label expansion approval for treatment of chronic hepatitis C virus: North Chicago Saturday, June 14, 2025, 11:00 Hrs [IST] AbbVie announced tha ...

To obtain full approval of the drug for treatment of chemotherapy-induced diarrhea (CID) and to expand the indication of ...

FDA approved a label expansion for Mavyret for the treatment of acute hepatitis C virus, according to a press release from the manufacturer, AbbVie.